Esco Aster announced CMC manufacturing support for Shine-On Biomedical's HLA-G targeted exosome programme. Shine-On Biomedical sponsored Esco Aster in 2023 for cGMP services, starting with high-yield exosome development using Esco Aster's cell line platform. The technical reports of process, analytical and formulation development, exosome drug loading, GMP engineering runs and stability studies supported Shine-On's IND submission. The IND was cleared by the US Food and Drug Administration (FDA) in Q1 2025. 

Furthermore, Esco Aster is providing technical services for exploratory exosome loading feasibility studies, as per Shine-On's instruction. Shine-On Biomedical is an emerging innovator in exosome-based drug delivery. 

ShineOn's proprietary product, SOB100, a HLA-G targeted exosome drug delivery carrier, has passed the US FDA IND review and ongoing phase-I study, making it as a first-in-class–potential HLA-G targeted exosome platform for drug development. 

Speaking in this regard, Hung-Che Chiang, General Manager, Shine-On Biomedical, said, "Pre-clinical studies have shown promising biodistribution characteristics supporting further exploration across small-molecule, nucleic acid and protein-based payloads."

In parallel, Esco Aster is providing Mitosis Enterprise Solutions to support potential future evaluation of single-use cGMP workflows at China Medical University Hospital.

This collaboration strengthens Esco Aster's position as Singapore's first fully homegrown CRDMO offering end-to-end engineered cancer exosome development—from cell line creation to GMP manufacturing using its patented 3D Tide Motion bioreactor. This technology lowers COGS by enabling multiple conditioned media harvests per run. Esco Aster also co-develops autologous cell therapy programmes in ASEAN, including a T-cell reactivation platform targeting non-G12C KRAS mutation NSCLC.

Esco Aster supports Asia-Pacific innovators through biomanufacturing scale-up, market access and commercialisation across South Asia, ASEAN and Oceania—a region valued at ~USD 10.5 trillion GDP with ~2.6 billion people.

Supported by a network of medical centres and clinician-scientists, Esco Aster facilitates IIT and FIM studies, especially in Australia, where R&D incentives lower costs. The company advances its "One World BioSolutions for One Health" vision, enabling high yield at low GMP cost to strengthen Singapore's and Asia's bioeconomy.